https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-04-21 16:18:432022-04-22 16:19:11EIB provides €15 million to fund coronavirus research at IRBM
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-03-31 15:52:402022-04-08 15:56:16TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-03-15 09:22:562022-03-16 09:23:10Etcembly Appoints Scott Cuthill as Chief Business Officer
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-02-21 13:42:492022-02-21 13:42:49BC Platforms Adds Japan’s Mitsubishi Space Software to its Global Data Network
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-02-09 15:36:192022-02-10 15:39:16Orthox Closes $12.5m Series A Financing for Clinical Trials of Knee Cartilage Repair FibroFix™ Product Platform
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-01-27 15:31:432022-02-10 15:35:28SiSaf Announces Michael J. Econs MD, World-leading Expert in Metabolic Bone Disease, as Clinical Advisor
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-01-18 15:10:052022-01-18 15:10:05Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
https://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.png00Ethan Assorhttps://www.sciuscommunications.com/wp/wp-content/uploads/2020/07/Scius_logo_250px.pngEthan Assor2022-01-06 10:15:582022-01-10 10:20:28Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Other cookies
The following cookies are also needed - You can choose if you want to allow them:
